LabGenius, a London, UK-based developer of an AI driven drug discovery platform, raised $10m in Series A funding.
The round was led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Gigafund, Air Street Capital, Recursion Pharmaceuticals’ Founder & CEO Chris Gibson as well as Inovia Capital General Partner Patrick Pichette who was formerly Google’s CFO. In conjunction with the funding, Zavain Dar, Partner at Lux Capital and Nan Li, Managing Director at Obvious Ventures, will join LabGenius’ board of directors.
The company will use the capital to scale its team, expand the scope of its discovery platform, and initiate an internal asset development program.
Led by Dr James Field, CEO and Founder, LabGenius is a drug discovery company that is using artificial intelligence (AI), robotic automation, and synthetic biology to discover novel protein therapeutics.
The company has developed EVA – a scientist capable of designing, conducting, and learning from its own experiments. Importantly, the learning aspect means that EVA gets continuously smarter as it unpicks the genetic design rules that underpin life.